THERAPY DOSSIER · th-3d58aab2f600

Astrocyte-targeted constitutively active CREB (VP16-CREB) expressed via a Tet-Off bitransgenic system

Other

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: TBI
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 26880229 ↗2016Reported benefit

Targeted activation of CREB in reactive astrocytes is neuroprotective in focal acute cortical injury.

MouseTBIUnspecifiedC57BL/6 background bitransgenic (Tet-Off astrocyte-targeted VP16-CREB) and wild-type littermatesMale and femaleTransgenic expression, no exogenous administrationTransgene expressed before injury (constitutive, Tet-Off regulated)

Model: Focal acute cortical injury (experimental traumatic brain injury)

Bitransgenic mice expressing VP16-CREB in astrocytes showed less neuronal death and damage, reduced macrophage infiltration, preserved mitochondria and rescued expression of mitochondrial metabolism genes compared with wild-type littermates. A core set of candidate VP16-CREB target genes was identi…

Extraction: extract · Supplied extraction confidence: 0.65. Machine-extracted fields require source verification.

Loading the evidence…